Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462533408> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2462533408 endingPage "361" @default.
- W2462533408 startingPage "353" @default.
- W2462533408 abstract "Introduction of new antibiotics enabling single-dose administration, such as oritavancin may significantly impact site of care decisions for patients with acute bacterial skin and skin structure infections (ABSSSI). This analysis compared the efficacy of single-dose oritavancin with multiple-dose vancomycin in patients categorized according to disease severity via modified Eron classification and management setting. SOLO I and II were phase 3 studies evaluating single-dose oritavancin versus 7–10 days of vancomycin for treatment of ABSSSI. Patient characteristics were collected at baseline and retrospectively analyzed. Study protocols were amended, allowing outpatient management at the discretion of investigators. In this post hoc analysis, patients were categorized according to a modified Eron severity classification and management setting (outpatient vs. inpatient) and the efficacy compared. Overall, 1910 patients in the SOLO trials were categorized into Class I (520, 26.5%), II (790, 40.3%), and III (600, 30.6%). Of the 767 patients (40%) in the SOLO trials who were managed entirely in the outpatient setting 40.3% were categorized as Class II and 30.6% were Class III. Clinical efficacy was similar between oritavancin and vancomycin treatment groups, regardless of severity classification and across inpatient and outpatient settings. Class III patients had lower response rates (oritavancin 73.3%, vancomycin 76.6%) at early clinical evaluation when compared to patients in Class I (82.6%) or II (86.1%); however, clinical cure rates at the post-therapy evaluation were similar for Class III patients (oritavancin 79.8%, vancomycin 79.9%) when compared to Class I and II patients (79.1–85.7%). Single-dose oritavancin therapy results in efficacy comparable to multiple-dose vancomycin in patients categorized according to modified Eron disease severity classification regardless of whether management occurred in the inpatient or outpatient setting. The Medicines Company, Parsippany, NJ, USA. ClinicalTrials.gov identifiers, NCT01252719 (SOLO I) and NCT01252732 (SOLO II)." @default.
- W2462533408 created "2016-07-22" @default.
- W2462533408 creator A5026253603 @default.
- W2462533408 creator A5057825659 @default.
- W2462533408 creator A5059959498 @default.
- W2462533408 creator A5060131932 @default.
- W2462533408 creator A5071196571 @default.
- W2462533408 creator A5078840423 @default.
- W2462533408 creator A5089156953 @default.
- W2462533408 date "2016-07-01" @default.
- W2462533408 modified "2023-09-27" @default.
- W2462533408 title "Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting" @default.
- W2462533408 cites W1587625029 @default.
- W2462533408 cites W1964024657 @default.
- W2462533408 cites W2022265152 @default.
- W2462533408 cites W2091382682 @default.
- W2462533408 cites W2116814997 @default.
- W2462533408 cites W2136609531 @default.
- W2462533408 cites W2141015770 @default.
- W2462533408 cites W2141609296 @default.
- W2462533408 cites W2161621663 @default.
- W2462533408 cites W91579775 @default.
- W2462533408 doi "https://doi.org/10.1007/s40121-016-0119-9" @default.
- W2462533408 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5019983" @default.
- W2462533408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27565805" @default.
- W2462533408 hasPublicationYear "2016" @default.
- W2462533408 type Work @default.
- W2462533408 sameAs 2462533408 @default.
- W2462533408 citedByCount "15" @default.
- W2462533408 countsByYear W24625334082017 @default.
- W2462533408 countsByYear W24625334082018 @default.
- W2462533408 countsByYear W24625334082019 @default.
- W2462533408 countsByYear W24625334082020 @default.
- W2462533408 countsByYear W24625334082021 @default.
- W2462533408 countsByYear W24625334082022 @default.
- W2462533408 countsByYear W24625334082023 @default.
- W2462533408 crossrefType "journal-article" @default.
- W2462533408 hasAuthorship W2462533408A5026253603 @default.
- W2462533408 hasAuthorship W2462533408A5057825659 @default.
- W2462533408 hasAuthorship W2462533408A5059959498 @default.
- W2462533408 hasAuthorship W2462533408A5060131932 @default.
- W2462533408 hasAuthorship W2462533408A5071196571 @default.
- W2462533408 hasAuthorship W2462533408A5078840423 @default.
- W2462533408 hasAuthorship W2462533408A5089156953 @default.
- W2462533408 hasBestOaLocation W24625334081 @default.
- W2462533408 hasConcept C126322002 @default.
- W2462533408 hasConcept C141071460 @default.
- W2462533408 hasConcept C2778980435 @default.
- W2462533408 hasConcept C2779489039 @default.
- W2462533408 hasConcept C2992886853 @default.
- W2462533408 hasConcept C523546767 @default.
- W2462533408 hasConcept C535046627 @default.
- W2462533408 hasConcept C54355233 @default.
- W2462533408 hasConcept C67761136 @default.
- W2462533408 hasConcept C71924100 @default.
- W2462533408 hasConcept C86803240 @default.
- W2462533408 hasConceptScore W2462533408C126322002 @default.
- W2462533408 hasConceptScore W2462533408C141071460 @default.
- W2462533408 hasConceptScore W2462533408C2778980435 @default.
- W2462533408 hasConceptScore W2462533408C2779489039 @default.
- W2462533408 hasConceptScore W2462533408C2992886853 @default.
- W2462533408 hasConceptScore W2462533408C523546767 @default.
- W2462533408 hasConceptScore W2462533408C535046627 @default.
- W2462533408 hasConceptScore W2462533408C54355233 @default.
- W2462533408 hasConceptScore W2462533408C67761136 @default.
- W2462533408 hasConceptScore W2462533408C71924100 @default.
- W2462533408 hasConceptScore W2462533408C86803240 @default.
- W2462533408 hasIssue "3" @default.
- W2462533408 hasLocation W24625334081 @default.
- W2462533408 hasLocation W24625334082 @default.
- W2462533408 hasLocation W24625334083 @default.
- W2462533408 hasLocation W24625334084 @default.
- W2462533408 hasLocation W24625334085 @default.
- W2462533408 hasOpenAccess W2462533408 @default.
- W2462533408 hasPrimaryLocation W24625334081 @default.
- W2462533408 hasRelatedWork W2172501371 @default.
- W2462533408 hasRelatedWork W2175727232 @default.
- W2462533408 hasRelatedWork W2590564118 @default.
- W2462533408 hasRelatedWork W2883766095 @default.
- W2462533408 hasRelatedWork W2981746196 @default.
- W2462533408 hasRelatedWork W3040846247 @default.
- W2462533408 hasRelatedWork W3094811507 @default.
- W2462533408 hasRelatedWork W3097527510 @default.
- W2462533408 hasRelatedWork W4200556704 @default.
- W2462533408 hasRelatedWork W4307957519 @default.
- W2462533408 hasVolume "5" @default.
- W2462533408 isParatext "false" @default.
- W2462533408 isRetracted "false" @default.
- W2462533408 magId "2462533408" @default.
- W2462533408 workType "article" @default.